

Neeraj Dhaun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1977975/publications.pdf>

Version: 2024-02-01

121
papers

4,371
citations

136950

32
h-index

118850

62
g-index

164
all docs

164
docs citations

164
times ranked

5985
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin in obese pregnancy has no adverse effects on cardiovascular risk in early childhood. <i>Journal of Developmental Origins of Health and Disease</i> , 2022, 13, 390-394.	1.4	8
2	Utility of interval kidney biopsy in ANCA-associated vasculitis. <i>Rheumatology</i> , 2022, 61, 1966-1974.	1.9	11
3	Comment on: A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG PET/CT: a Chinese cohort study. <i>Rheumatology</i> , 2022, 61, SI97-SI98.	1.9	2
4	Strawberry carina as a presentation of anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2022, 61, e59-e61.	1.9	0
5	The impact of excessive salt intake on human health. <i>Nature Reviews Nephrology</i> , 2022, 18, 321-335.	9.6	46
6	The changing role of glucocorticoids in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Kidney International</i> , 2022, 101, 201-204.	5.2	1
7	High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with kidney impairment. <i>Kidney International</i> , 2022, 102, 149-159.	5.2	9
8	Cardiovascular outcomes in patients with chronic kidney disease and COVID-19: a multi-regional data-linkage study. <i>European Respiratory Journal</i> , 2022, 60, 2103168.	6.7	8
9	Apelin is expressed throughout the human kidney, is elevated in chronic kidney disease & associates independently with decline in kidney function. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 5295-5306.	2.4	3
10	Novel retinal vascular phenotypes for the potential assessment of long-term risk in living kidney donors. <i>Kidney International</i> , 2022, 102, 661-665.	5.2	1
11	Multimorbidity in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results From a Longitudinal, Multicenter Data Linkage Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 651-659.	5.6	5
12	Activation of the Sympathetic Nervous System Promotes Blood Pressure Salt-Sensitivity in C57BL/6J Mice. <i>Hypertension</i> , 2021, 77, 158-168.	2.7	19
13	Hypertension and Vascular Inflammation. <i>Hypertension</i> , 2021, 77, 190-192.	2.7	6
14	Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease. <i>IScience</i> , 2021, 24, 101937.	4.1	16
15	Aortitis: recent advances, current concepts and future possibilities. <i>Heart</i> , 2021, 107, 1620-1629.	2.9	18
16	Resolving thromboinflammation. <i>Blood</i> , 2021, 137, 1444-1446.	1.4	0
17	Antineutrophil cytoplasm antibody positivity, kidney impairment, and cholesterol embolization. <i>Kidney International</i> , 2021, 99, 774.	5.2	0
18	ANCA-associated renal vasculitis is associated with rurality but not seasonality or deprivation in a complete national cohort study. <i>RMD Open</i> , 2021, 7, e001555.	3.8	10

#	ARTICLE	IF	CITATIONS
19	STARMEN: progress in membranous nephropathy?. <i>Kidney International</i> , 2021, 99, 1242-1243.	5.2	1
20	Hypertension: Current trends and future perspectives. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3721-3736.	2.4	18
21	Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 456-465.	2.0	19
22	Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1713-1719.	5.6	35
23	A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology International</i> , 2021, 41, 1811-1814.	3.0	6
24	The therapeutic potential of apelin in kidney disease. <i>Nature Reviews Nephrology</i> , 2021, 17, 840-853.	9.6	39
25	Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, CJN.01930221.	4.5	6
26	Use of High-Sensitivity Cardiac Troponin in Patients With Kidney Impairment. <i>JAMA Internal Medicine</i> , 2021, 181, 1237.	5.1	9
27	Infective Endocarditis Hospitalizations and Outcomes in Patients With End-Stage Kidney Disease: A Nationwide Data-Linkage Study. <i>Journal of the American Heart Association</i> , 2021, 10, e022002.	3.7	5
28	Glucocorticoid-free treatment of severe ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 739-742.	0.7	6
29	Serial troponin measurements to monitor risk and response to endothelin A antagonism in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 375-377.	0.7	1
30	The acute pressure natriuresis response is suppressed by selective ETA receptor blockade. <i>Clinical Science</i> , 2021, , .	4.3	2
31	Large-vessel vasculitis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 93.	30.5	74
32	Forgotten signs of chronic kidney disease-associated mineral bone disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 359-360.	0.5	0
33	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2020, 177, 5467-5488.	5.4	65
34	Long-term outcomes in elderly patients with ANCA-associated vasculitis. <i>Rheumatology</i> , 2020, 59, 1076-1083.	1.9	37
35	Transfer of hepatocellular microRNA regulates cytochrome P450 2E1 in renal tubular cells. <i>EBioMedicine</i> , 2020, 62, 103092.	6.1	11
36	Coronary vasospasm in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2020, 59, e144-e146.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Deletion of the myeloid endothelin-B receptor confers long-term protection from angiotensin II-mediated kidney, eye and vessel injury. <i>Kidney International</i> , 2020, 98, 1193-1209.	5.2	8
38	The Eye as a Non-Invasive Window to the Microcirculation in Liver Cirrhosis: A Prospective Pilot Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3332.	2.4	11
39	Characterizing infection in anti-neutrophil cytoplasmic antibody-associated vasculitis: results from a longitudinal, matched-cohort data linkage study. <i>Rheumatology</i> , 2020, 59, 3014-3022.	1.9	15
40	Resistant Hypertension in a Dialysis Patient. <i>Hypertension</i> , 2020, 76, 278-287.	2.7	1
41	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines—Executive summary. <i>Rheumatology</i> , 2020, 59, 727-731.	1.9	5
42	The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons. <i>Kidney International</i> , 2020, 98, 323-342.	5.2	72
43	ANCA associated vasculitis. <i>BMJ</i> , The, 2020, 369, m1070.	6.0	43
44	Extracellular RNA in kidney disease: moving slowly but surely from bench to bedside. <i>Clinical Science</i> , 2020, 134, 2893-2895.	4.3	5
45	The tetraspanin CD9 controls migration and proliferation of parietal epithelial cells and glomerular disease progression. <i>Nature Communications</i> , 2019, 10, 3303.	12.8	52
46	Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.7	16
47	Developments in the Role of Endothelin-1 in Atherosclerosis: A Potential Therapeutic Target?. <i>American Journal of Hypertension</i> , 2019, 32, 813-815.	2.0	18
48	Advances in Therapies and Imaging for Systemic Vasculitis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1520-1541.	2.4	19
49	Retinal fingerprints for precision profiling of cardiovascular risk. <i>Nature Reviews Cardiology</i> , 2019, 16, 379-381.	13.7	12
50	Endothelins in cardiovascular biology and therapeutics. <i>Nature Reviews Cardiology</i> , 2019, 16, 491-502.	13.7	154
51	011.â€fCHORIORETINAL THICKNESS TRACKS DISEASE ACTIVITY IN CLINICAL ANCA VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
52	Management of Hypertension in Chronic Kidney Disease. <i>Drugs</i> , 2019, 79, 365-379.	10.9	196
53	Cyclophosphamide-Induced Lung Injury. <i>Kidney International Reports</i> , 2019, 4, 484-486.	0.8	8
54	A novel role for myeloid endothelin-B receptors in hypertension. <i>European Heart Journal</i> , 2019, 40, 768-784.	2.2	31

#	ARTICLE	IF	CITATIONS
55	Impaired pressure natriuresis and non-dipping blood pressure in rats with early type 1 diabetes mellitus. <i>Journal of Physiology</i> , 2019, 597, 767-780.	2.9	11
56	The Role of the Endothelin System in the Progression of Acute Kidney Injury to Chronic Kidney Disease. <i>FASEB Journal</i> , 2019, 33, 748.12.	0.5	0
57	Endothelin antagonism reduces circulating galectin-3 in patients with proteinuric chronic kidney disease. <i>Kidney International</i> , 2018, 93, 270.	5.2	3
58	High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients With Renal Impairment Presenting With Suspected Acute Coronary Syndrome. <i>Circulation</i> , 2018, 137, 425-435.	1.6	74
59	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I. <i>Journal of Hypertension</i> , 2018, 36, 451-461.	0.5	19
60	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II. <i>Journal of Hypertension</i> , 2018, 36, 462-471.	0.5	13
61	Neurological Disease in Lupus: Toward a Personalized Medicine Approach. <i>Frontiers in Immunology</i> , 2018, 9, 1146.	4.8	36
62	The role of endothelin in immune-mediated vascular injury. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, SY56-4.	0.0	0
63	Management of hypertension in chronic kidney disease. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, SY3-2.	0.0	0
64	Hypertension and Its Complications in a Young Man With Autoimmune Disease. <i>Hypertension</i> , 2017, 69, 536-544.	2.7	1
65	First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis. <i>Hypertension</i> , 2017, 70, 192-200.	2.7	7
66	Resolution of Hypoglycemia and Cardiovascular Dysfunction After Rituximab Treatment of Insulin Autoimmune Syndrome. <i>Diabetes Care</i> , 2017, 40, e80-e82.	8.6	13
67	In Absentia: Lupus-Like Nephritis with Seronegative Antiphospholipid Syndrome. <i>American Journal of Medicine</i> , 2017, 130, 805-808.	1.5	1
68	Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling. <i>Hypertension</i> , 2017, 69, 275-285.	2.7	12
69	Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis. <i>Nature Communications</i> , 2017, 8, 1829.	12.8	50
70	Pulse-wave velocity is associated with cognitive impairment in haemodialysis patients. <i>Clinical Science</i> , 2017, 131, 1495-1498.	4.3	4
71	The effect of renal dysfunction and haemodialysis on circulating liver specific miR-122. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 584-592.	2.4	17
72	Endemic Nephropathy Around the World. <i>Kidney International Reports</i> , 2017, 2, 282-292.	0.8	116

#	ARTICLE	IF	CITATIONS
73	Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism. <i>Theranostics</i> , 2017, 7, 2757-2774.	10.0	27
74	Arterial stiffness & Sri Lankan chronic kidney disease of unknown origin. <i>Scientific Reports</i> , 2016, 6, 32599.	3.3	6
75	Endothelin. <i>Pharmacological Reviews</i> , 2016, 68, 357-418.	16.0	574
76	Therapeutic potential of endothelin receptor antagonism in kidney disease. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 310, R388-R397.	1.8	18
77	Glucocorticoids Induce Nondipping Blood Pressure by Activating the Thiazide-Sensitive Cotransporter. <i>Hypertension</i> , 2016, 67, 1029-1037.	2.7	61
78	Hypertensive Encephalopathy and Renal Failure in a Young Man. <i>Hypertension</i> , 2016, 67, 6-13.	2.7	3
79	Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. <i>JCI Insight</i> , 2016, 1, e89173.	5.0	70
80	Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 343.	1.9	5
81	Targeting Blood Vessel Stiffness to Protect Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2107-2109.	4.5	2
82	Plasma Pro-Endothelin-1 Peptide Concentrations Rise in Chronic Kidney Disease and Following Selective Endothelin A Receptor Antagonism. <i>Journal of the American Heart Association</i> , 2015, 4, e001624.	3.7	16
83	Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease. <i>Journal of Lipid Research</i> , 2015, 56, 413-422.	4.2	70
84	Endothelin in Nondiabetic Chronic Kidney Disease: Preclinical and Clinical Studies. <i>Seminars in Nephrology</i> , 2015, 35, 176-187.	1.6	13
85	Alemtuzumab induction therapy in kidney transplantation. <i>Lancet, The</i> , 2015, 385, 770.	13.7	1
86	Utility of 18 F-Fluorodeoxyglucose Positron Emission Tomography Computed Tomography in the Diagnosis and Management of Aortitis. <i>Circulation</i> , 2015, 132, 1937-1938.	1.6	2
87	The Authors Reply. <i>Kidney International</i> , 2014, 86, 1269.	5.2	2
88	Diurnal Variation in Blood Pressure and Arterial Stiffness in Chronic Kidney Disease. <i>Hypertension</i> , 2014, 64, 296-304.	2.7	49
89	The characterisation and determinants of quality of life in ANCA associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 207-211.	0.9	74
90	Utility of renal biopsy in the clinical management of renal disease. <i>Kidney International</i> , 2014, 85, 1039-1048.	5.2	95

#	ARTICLE	IF	CITATIONS
91	Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: Clinical associations. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 521-527.	0.6	33
92	Endothelin Antagonism and Its Role in the Treatment of Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 489-496.	3.5	27
93	NSAIDs and nephrocalcinosis. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2103-2104.	1.9	2
94	Novel therapeutic approaches to chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 491-494.	2.4	0
95	Measurement of renal function in patients with chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 504-515.	2.4	54
96	Computed Tomography Angiography in the Diagnosis of ANCA-Associated Small- and Medium-Vessel Vasculitis. <i>American Journal of Kidney Diseases</i> , 2013, 62, 390-393.	1.9	13
97	The road from AKI to CKD: the role of endothelin. <i>Kidney International</i> , 2013, 84, 637-638.	5.2	24
98	Endothelin-A Receptor Antagonism Modifies Cardiovascular Risk Factors in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 31-36.	6.1	33
99	Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of End Points in Noninsulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial. <i>Hypertension</i> , 2012, 59, e1.	2.7	3
100	Endothelin and the kidney – beyond BP. <i>British Journal of Pharmacology</i> , 2012, 167, 720-731.	5.4	64
101	What is the best method of proteinuria measurement in clinical trials of endothelin receptor antagonists?. <i>Life Sciences</i> , 2012, 91, 733-738.	4.3	6
102	Chronic Selective Endothelin A Receptor Antagonism Reduces Serum Uric Acid in Hypertensive Chronic Kidney Disease. <i>Hypertension</i> , 2011, 58, e11-2.	2.7	12
103	Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. <i>Atherosclerosis</i> , 2011, 216, 217-225.	0.8	65
104	Circulating microRNAs as potential markers of human drug-induced liver injury. <i>Hepatology</i> , 2011, 54, 1767-1776.	7.3	464
105	Selective Endothelin-A Receptor Antagonism Reduces Proteinuria, Blood Pressure, and Arterial Stiffness in Chronic Proteinuric Kidney Disease. <i>Hypertension</i> , 2011, 57, 772-779.	2.7	138
106	Endothelin Antagonism in Patients with Nondiabetic Chronic Kidney Disease. <i>Contributions To Nephrology</i> , 2011, 172, 243-254.	1.1	11
107	Receptor Tyrosine Kinase Inhibition, Hypertension, and Proteinuria. <i>Hypertension</i> , 2010, 56, 575-577.	2.7	17
108	Greater Functional ET Receptor Antagonism With Bosentan Than Sitaxsentan in Healthy Men. <i>Hypertension</i> , 2010, 55, 1406-1411.	2.7	14

#	ARTICLE	IF	CITATIONS
109	Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. American Journal of Physiology - Renal Physiology, 2009, 296, F1477-F1483.	2.7	67
110	Blood Pressure-Independent Reduction in Proteinuria and Arterial Stiffness After Acute Endothelin-A Receptor Antagonism in Chronic Kidney Disease. Hypertension, 2009, 54, 113-119.	2.7	113
111	Effects of Endothelin Receptor Antagonism Relate to the Degree of Renin-Angiotensin System Blockade in Chronic Proteinuric Kidney Disease. Hypertension, 2009, 54, e19-20.	2.7	23
112	Endothelin Receptor Antagonism and Renin Inhibition as Treatment Options for Scleroderma Kidney. American Journal of Kidney Diseases, 2009, 54, 726-731.	1.9	38
113	TWEAK: a novel biomarker for lupus nephritis?. Arthritis Research and Therapy, 2009, 11, 133.	3.5	9
114	Endothelin-receptor antagonism: the future is bright. Lancet, The, 2008, 371, 2061-2062.	13.7	7
115	Role of Endothelin-1 in Clinical Hypertension. Hypertension, 2008, 52, 452-459.	2.7	150
116	Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 22, 3228-3234.	0.7	47
117	Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends in Pharmacological Sciences, 2007, 28, 573-579.	8.7	67
118	The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment. British Journal of Clinical Pharmacology, 2007, 64, 733-737.	2.4	15
119	The Endothelin System and Its Antagonism in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 943-955.	6.1	216
120	Vasodilator effects of the endothelin ET _A receptor selective antagonist BMS-193884 in healthy men. British Journal of Clinical Pharmacology, 2005, 60, 611-622.	2.4	5
121	Renin-Angiotensin and Endothelin Systems in Patients Post-Takotsubo Cardiomyopathy. Journal of the American Heart Association, 0, , .	3.7	2